Free Trial
NASDAQ:CGEM

Cullinan Therapeutics Q2 2026 Earnings Results & Report

Cullinan Therapeutics logo
$10.28 +0.09 (+0.88%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$10.27 -0.01 (-0.10%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cullinan Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.81 versus the -$0.7993 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Cullinan Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.7993
Beat/Miss
Missed by -$0.0107
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cullinan Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.67 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cullinan Therapeutics Q2 2026 Earnings FAQ

Cullinan Therapeutics (NASDAQ:CGEM) reported earnings of -$0.81 per share for Q2 2026, missing the consensus estimate of -$0.7993. The report was announced on Thursday, August 6, 2026.

Cullinan Therapeutics Earnings Headlines

Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $44.00
BTIG Reaffirms Their Buy Rating on Cullinan Management (CGEM)
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Cullinan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cullinan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cullinan Therapeutics and other key companies, straight to your email.

About Cullinan Therapeutics

Cullinan Therapeutics (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells.

Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases. These candidates remain investigational and are not approved treatments.

Founded as Cullinan Oncology, the company adopted the name Cullinan Therapeutics in 2024 to reflect its expanded focus beyond oncology. It is headquartered in Cambridge, Massachusetts, and is led by President and Chief Executive Officer Nadim Ahmed.

View Cullinan Therapeutics Profile